Processing Ac-227 sources for lead-212 and radium-223 required by cancer research

处理癌症研究所需的 Ac-227 来源的铅 212 和镭 223

• 批准号: 7272640
• 负责人: Chuck Z Soderquist
• 金额: $ 11.13万
• 依托单位: ALPHAMED, INC
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-28 至 2009-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7272640
• 关键词: Actinium; American Cancer Society; Animals; Applications Grants; Clinical Trials; Conduct Clinical Trials; Contracts; Databases; Daughter; Diagnosis; Disease; Disease remission; Dose; Ensure; Evaluation; Funding; Grant; Half-Life; Isotopes; Label; Life Extension; Malignant Neoplasms; Malignant neoplasm of pancreas; Medical; Medical Research; Medicine; Metastatic Melanoma; Metastatic Neoplasm to the Bone; Methods; Missouri; Modification; Neoplasm Metastasis; Neutrons; Norway; Nuclear; Operative Surgical Procedures; Paper; Parents; Pharmaceutical Preparations; Phase; Preclinical Testing; Preparation; Process; Production; Publishing; Purpose; Radioisotopes; Radiolabeled; Radium; Radium-224; Recycling; Research; Research Personnel; Roche brand of trastuzumab; Schedule; Shipping; Ships; Small Business Technology Transfer Research; Source; Staging; Targeted Radiotherapy; Techniques; Testing; Therapeutic Effect; Thorium; United States National Institutes of Health; Universities; anticancer research; base; bone; cancer therapy; day; improved; irradiation; programs; radiotracer; wasting

DESCRIPTION (provided by applicant): NIH sponsored cancer researchers have been obtaining promising results using molecules radiolabeled with lead-212 in treatment for metastatic melanoma and disseminated colon and pancreatic cancers. Another isotope, radium-223 is being used in clinical trials in treatment of skeletal metastases. There is no effective therapy for these diseases. Together 199,280 people in the US will be diagnosed this year and 97,070 will die from these diseases (American Cancer Society 2005 Cancer Facts and Figures). This promising cancer research must be supported with additional quantities of the isotope if this research is to proceed to later stage clinical trials and approved drug products. Also, additional amounts of the isotopes are required to support increased research on other cancers that will be undertaken as papers are published discussing the therapeutic effect achieved in current research. This grant application will increase the amount of these isotopes by processing and purifying actinium-227, an isotope used in the production of neutron generators produced years ago and are now being disposed of. Two sources have been obtained, totaling 1.5 Ci. Actinium-227 once purified can be processed for Ra-223. It can also be irradiated to produce thorium-228, a precursor isotope to Pb-212. As a result of implementing this Phase I grant application, Ac-227 will be separated from these sources and separation techniques yielding high quality Ra-223 will be demonstrated. Additional sources of Ac-227 will be identified and candidate reactors for Ac-227 irradiations required for the production of Th-228 will be identified. As a result of implementing a Phase II grant, curie quantities of Ra-223 and Th-228/Pb-212 will be available at purity levels required for medical research. -Relevance This Phase I grant application and a follow-on Phase II application proposes to increase the amount of radioisotopes required to support later stage research and anticipated approved drug products in therapies that are showing promise in cancer therapies. NIH funded researchers have been obtaining promising results using molecules radiolabeled with lead-212 in treatment for metastatic melanoma and disseminated colon and pancreatic cancers. Another isotope, radium-223 is being used in clinical trials in treatment of skeletal metastases.

描述（由申请人提供）：NIH赞助的癌症研究人员使用铅-212放射性标记的分子治疗转移性黑色素瘤和播散性结肠癌和胰腺癌，已经获得了有希望的结果。另一种同位素镭-223正用于治疗骨转移的临床试验。这些疾病没有有效的治疗方法。今年美国将有199，280人被诊断出患有这些疾病，97，070人将死于这些疾病（美国癌症协会2005年癌症事实和数据）。如果这项研究要进入后期临床试验和批准的药物产品，这项有前途的癌症研究必须得到额外数量的同位素的支持。此外，需要额外数量的同位素来支持对其他癌症的研究，这些癌症将在讨论当前研究所取得的治疗效果的论文发表时进行。这项拨款申请将通过处理和纯化锕-227来增加这些同位素的数量，锕-227是一种用于生产中子发生器的同位素，多年前生产，现在正在处理。已获得两个源，总计1.5 Ci。锕-227一旦纯化，就可以加工成Ra-223。它也可以被辐照产生钍-228，一种铅-212的前体同位素。作为实施第一阶段赠款申请的结果，Ac-227将从这些来源中分离出来，并将展示产生高质量Ra-223的分离技术。将确定其他Ac-227来源，并确定生产Th-228所需的Ac-227辐照候选反应堆。由于实施了第二阶段赠款，将可获得医学研究所需纯度水平的居里数量的Ra-223和Th-228/Pb-212。- 相关性第一阶段拨款申请和后续第二阶段申请建议增加所需的放射性同位素的数量，以支持后期研究和预期批准的药物产品，这些药物在癌症治疗中显示出希望。美国国立卫生研究院资助的研究人员已经获得了有希望的结果，使用放射性标记的铅-212分子治疗转移性黑色素瘤和播散性结肠癌和胰腺癌。另一种同位素镭-223正用于治疗骨转移的临床试验。